USPTO Trademark Application for SOL-MOIETY

ChangeBridge: Trademarks - Legal & Security (Class 045)

Detected March 26th, 2026

Summary

The USPTO has published an intent-to-use trademark application for the mark SOL-MOIETY, filed on May 14, 2025. The application covers licensing of technology in pharmaceuticals, medicine, and biotechnology, as well as pharmaceutical preparations like water-soluble prodrugs and drug carriers.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has published an intent-to-use trademark application (TM99185291) for the mark SOL-MOIETY. The application, filed on May 14, 2025, pertains to licensing of technology in the fields of pharmaceuticals, medicine, and biotechnology, including chemical reagents, water-soluble pharmaceutical products, and patents. It also covers pharmaceutical preparations such as a drug delivery system using water-soluble prodrugs and drug carriers for oral delivery of therapeutically active compounds.

This filing represents a new trademark application and does not impose immediate compliance obligations on regulated entities. However, it signals potential future market activity and intellectual property claims by the applicant in the pharmaceutical and biotechnology sectors. Companies operating in these areas should be aware of this application as it may affect their own branding or product development strategies.

Source document (simplified)

← USPTO Trademark Applications

SOL-MOIETY

Intent to Use TM99185291 Kind: intenttouse Mar 20, 2026

Abstract

Licensing of technology in the field of pharmaceuticals, medicine, and biotechnology; licensing of chemical reagents and water-soluble pharmaceutical products; licensing of patents and patent applications; Pharmaceutical preparations, namely a drug delivery system in the form of water-soluble prodrugs that facilitate the solubility of a wide range of pharmaceuticals; drug carriers for medical use consisting of molecules that increase water-solubility of compounds for oral delivery of therapeutically active chemical compounds for human use; Research and development services in the field of water-soluble drug delivery technologies; Providing product development in the fields of drug delivery systems, small molecules, peptides, pharmaceuticals, and medicine; providing technological information in the fields of drug delivery systems, small molecules, peptides, pharmaceuticals, and medicine